EN DE

SSY Group Ltd (2005) Fair Value & Analysis

Healthcare · HK · Market cap HK$6.4B

SG SSY Group Ltd 2005 · HK
PriceHK$2.41
Fair ValueHK$2.82
Upside+17.3%
Quality48/100
Watch SSY Group Ltd for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Solidly profitable · 11.3% net margin
Low debt · generates free cash flow
3.77% dividend yield
Ranks above peers (11/15)
Narrow moat 40/100
Evidence: High Range HK$2.04 – HK$3.85 Share as image

Fair value as of: Aug 13, 2026

From 26 valuation models · updated 3 days ago

Share price −1.8% over the past month.

Below-average quality, screening 17% undervalued on our models.

What matters now

  • A fairly wide model range (HK$2.04 to HK$3.85) leaves room in how you read the outcome.
  • Our model range runs from HK$2.04 (bear) to HK$3.85 (bull), base HK$2.82. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 48/100 (below-average quality) with high evidence: the data supports the verdict.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

HK$6.72 HK$2.02 Fair Value HK$2.82 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$2.02 – HK$6.72 · fair‑value band HK$2.04 – HK$3.85 · the HK$2.41 price screens below the HK$2.82 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

SSY Group Ltd (2005) currently trades at HK$2.41, while our model-based Fair Value estimate is HK$2.82, implying the stock looks roughly 17.3% undervalued today. The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, SSY Group Ltd generated revenue of HK$4.2B at a net margin of 11.3%. Revenue declined 17.1% year over year. It earns a return on equity of 6.4%. Net debt stands at HK$2.2B. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$2.04 (bear case) to HK$3.85 (bull case); at HK$2.41, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 27% below its 52-week high and 20% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 17%, 2005 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF HK$0.9800 HK$1.52 HK$2.27 80
Residual Income HK$2.01 HK$2.10 HK$2.15 76
Rev-Margin DCF HK$1.46 HK$2.57 HK$3.86 74
All 26 models by family
DCF Models
FCF DCF HK$0.9700 HK$1.59 HK$2.51 38
Owner Earnings HK$2.06 HK$3.28 HK$5.09 31
5Y Revenue Exit HK$1.46 HK$2.58 HK$4.05 39
5Y EBITDA Exit HK$2.49 HK$4.54 HK$6.97 41
5Y P/E Exit HK$1.78 HK$3.19 HK$4.70 38
10Y Revenue Exit HK$1.20 HK$2.18 HK$3.53 36
10Y EBITDA Exit HK$1.91 HK$3.51 HK$5.73 37
10Y P/E Exit HK$1.46 HK$2.60 HK$4.02 35
Earnings-Based
Graham-Dodd HK$1.11 HK$3.62 HK$4.84 54
Lynch FV HK$0.8100 HK$1.16 HK$1.51 50
PEG = 1.0 HK$0.8100 HK$1.16 HK$1.51 46
EPV HK$1.56 HK$1.83 HK$2.07 59
Dividend Discount
Gordon GGM HK$1.30 HK$2.58 HK$3.91 70
DDM Multi-Stage HK$1.30 HK$2.16 HK$2.73 61
Multiples
P/E Multiple HK$2.69 HK$3.58 HK$4.48 63
P/S Multiple HK$2.08 HK$2.77 HK$3.46 58
P/B Multiple HK$2.08 HK$2.77 HK$3.46 55
EV/EBIT HK$2.61 HK$3.53 HK$4.46 53
EV/EBITDA HK$3.77 HK$5.08 HK$6.39 54
EV/Revenue HK$1.82 HK$2.66 HK$3.51 43
Asset-Based
NCAV (Graham) HK$1.26 HK$1.69 HK$2.53 50
Growth DCF
Growth DCF HK$0.9800 HK$1.52 HK$2.27 80
Rev-Margin DCF HK$1.46 HK$2.57 HK$3.86 74
Economic Profit
Residual Income HK$2.01 HK$2.10 HK$2.15 76
ROIC Compounder HK$1.56 HK$1.83 HK$2.07 72
Growth Earnings
Growth-Adj P/E HK$2.25 HK$3.21 HK$4.17 68

Widest divergence: Growth Earnings (HK$3.21) versus Earnings-Based (HK$1.16). Highest evidence: Growth DCF (80).

Notify me when 2005 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) HK$4.2B
Revenue growth (YoY) -17.1%
Net margin 11.3%
Return on equity 6.4%
Free cash flow HK$300M FY2025
P/E ratio 13.8 as of Jul 2, 2026
More key figures
Operating margin 11.1%
EPS (TTM) HK$0.1000
Dividend yield 3.8%
EPS growth (YoY) -49.5%
Net debt HK$2.2B FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 48/100

Of which business quality 48 · Market factors (momentum, volatility) 43

Profitability 32
Margins and returns on capital today
Quality Growth 1
Are margins and returns improving?
Cashflow 44
Earnings quality: real cash, not paper profit
Fin. Strength 59
Balance sheet, leverage, solvency risk
Investment 71
Disciplined investing over empire-building
Low Volatility 82
Calm price path (market factor)
Momentum 29
Price trend over the last 3–12 months (market factor)
52W Momentum 22
Distance to the 52-week high (market factor)
Net Issuance 90
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

SSY Group Limited, an investment holding company, researches, develops, manufactures, trades, and sells various pharmaceutical products to hospitals and distributors in the People's Republic of China and internationally.

Full company description

SSY Group Limited, an investment holding company, researches, develops, manufactures, trades, and sells various pharmaceutical products to hospitals and distributors in the People's Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC and upright soft bag, PP plastic bottle, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials. In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; food, beverages, and catering businesses; research, development of biotechnology and related roducts; and production and sale of methylamine. It sells its products under the Shimen brand name. The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. SSY Group Limited was founded in 1999 and is headquartered in Wan Chai, Hong Kong.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

SSY Group Ltd reported revenue of HK$4.2B in FY2025 versus HK$5.4B in FY2021, a compound −6.1%/yr. Reported net income was HK$471M in FY2025, compounding −12.0%/yr from FY2021.

Growth Quality 40/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
HK$4.2B
Latest YoY
−27.8%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−13.5%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−0.5%
Avg. growth/yr (23Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+7.1%
Revenue −6.1%/yr
FY21 HK$5.4B
FY22 HK$6.4B
FY23 HK$6.5B
FY24 HK$5.8B
FY25 HK$4.2B
Net income −12.0%/yr
FY21 HK$786M
FY22 HK$1.1B
FY23 HK$1.3B
FY24 HK$1.1B
FY25 HK$471M
Character of growth · EPS growth decomposed (2014-2025) +7.2 % p.a.
Revenue per share +10.3 pp

of which total revenue +10.5 pp · buybacks/dilution −0.2 pp

EBIT margin −2.4 pp
Tax rate −0.1 pp
Residual (interest, one-offs) −0.6 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

Watch 2005: get an alert when its fair value changes →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SSY Group Ltd · Fair Value
HK$2.82 +17%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "SSY Group Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2005

Peer Group

Drug Manufacturers - Specialty & Generic · 622 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 48 · Below median
Fair Value upside +17% · Above median
Return on equity (TTM) 6% · Above median
Return on assets 3% · Above median
Net margin (TTM) 11% · Above median
Operating margin (TTM) 11% · Above median
Revenue growth -17% · Bottom 25%
Dividend yield (TTM) 3.8% · Top 25%
Debt / equity 0.31× · Higher than 75% of peers

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (TTM) 13.8× · Cheaper than 75% of peers
P/B 0.88× · Cheaper than median
P/S (TTM) 1.53× · Cheaper than median
P/FCF 2.7× · Pricier than median
EV/EBITDA 6.6× · Cheaper than median
PEG 0.44× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 56 · sector 7
FUTURE 0 · sector 21
PAST 26 · sector 25
HEALTH 85 · sector 97
DIVIDEND 75 · sector 32

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥53.76 ¥25.94 -52%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,944 ₹989.50 -49%
Divi's Laboratories Limited DIVISLAB ₹8,500 ₹1,932 -77%
Torrent Pharmaceuticals Limited TORNTPHARM ₹4,915 ₹1,163 -76%
PharmaEssentia Corporation 6446 1,440 TWD 233.93 TWD -84%
Cipla Limited CIPLA ₹1,463 ₹1,001 -32%
Zydus Lifesciences Limited ZYDUSLIFE ₹1,167 ₹703.32 -40%
Lupin Limited LUPIN ₹2,281 ₹2,477 +9%
Mankind Pharma Limited MANKIND ₹2,433 ₹983.11 -60%
Dr. Reddy's Laboratories Limited DRREDDY ₹1,200 ₹874.79 -27%

Compare SSY Group Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is SSY Group Ltd (2005) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of HK$2.82 versus a price of HK$2.41, about +17% (undervalued).
What is the fair value of 2005?
Our model-based fair value for SSY Group Ltd is HK$2.82 (as of Aug 13, 2026), built from audited fundamentals. The current price is HK$2.41.
What is the quality score of 2005?
SSY Group Ltd has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of SSY Group Ltd (2005)?
SSY Group Ltd reported trailing-twelve-month revenue of about HK$4.2B (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 2005?
The net profit margin of SSY Group Ltd is about 11.3%, meaning it keeps roughly 11.3% of revenue as net income. Based on the latest reported figures.
Does SSY Group Ltd pay a dividend?
SSY Group Ltd currently shows a dividend yield of about 3.77% relative to its recent price (as of Aug 13, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track SSY Group Ltd and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.